StreetInsider.com News Articles

Century Therapeutics names Joseph Truitt to its board of directors

Wed, 09 Sep 2026 16:05:19 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Joseph Truitt to its board of directors, the biotechnology company announced.

Truitt currently serves as chief executive officer and board member of iECURE, Inc., a clinical-stage biotechnology company focused on genome-editing therapies. He also serves as chairman of the board of Larimar Therapeutics (NASDAQ: LRMR) and as a board member of Code Biotherapeutics.

Previously, Truitt was chief executive officer of BioSpecifics Technologies Corp. until its acquisition by Endo International plc in December 2020. Before that, he held several roles at Achillion Pharmaceuticals, including chief commercial officer, chief operating officer, and chief executive officer, prior to

Century Therapeutics names Joseph Truitt to its board of directors

Wed, 09 Sep 2026 16:05:19 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Joseph Truitt to its board of directors, the biotechnology company announced.

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors.

Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing genome-editing therapies for rare, life-threatening genetic diseases. He is Chairman of the Board of Larimar Therapeutics (NASDAQ: LRMR) and a member of the Board of Directors of Code

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 8c

Tue, 04 Aug 2026 07:24:56 -0400

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

Form 10-Q Larimar Therapeutics, For: Jun 30

Tue, 04 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260804/26861487.html

Form 10-Q Larimar Therapeutics, For: Jun 30

Tue, 04 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260804/26861487.html

Form 8-K Larimar Therapeutics, For: Aug 04

Tue, 04 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26861396.html

Form 8-K Larimar Therapeutics, For: Aug 04

Tue, 04 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26861396.html

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Form 4 Larimar Therapeutics, For: Jul 06 Filed by: Hamilton Thomas Edward

Wed, 08 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260708/26747571.html

Form 4 Larimar Therapeutics, For: Jul 06 Filed by: Hamilton Thomas Edward

Wed, 08 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260708/26747571.html

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’